Editas Medicine

Traded on the St. Petersburg Stock Exchange
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology.
Editas Medicine stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Editas Medicine balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Editas Medicine cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Editas Medicine multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Editas Medicine profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Editas Medicine assets
Editas Medicine cash flows

Editas Medicine shares

TickerNameTypeNominal valueISINPrice
EDIT:USEditas Medicine, Inc.Common share-US28106W1036$3.87
Editas Medicine news
13.05.2022
FDA has designated Editas Medicine's EDIT-301 candidate as an orphan drug for beta-thalassemia. Preparations are underway for a Phase 1/2 EDIT-301 clinical trial of the drug, which is planned for the end of the year.
Source: ir.editasmedicine.com pictogram ir.editasmedicine.com
Pictogram next
04.05.2022
Editas Medicine's GAAP loss for 3 months of 2022 was $50.515 million, down 11% from $56.728 million in the previous year.
Source: ir.editasmedicine.com pictogram ir.editasmedicine.com
Pictogram next
24.02.2022
Editas Medicine's GAAP loss for 2021 was $192.502 million, up 66% from $115.976 million in the previous year. Revenue declined 71.8% to $25.544 million from $90.732 million a year earlier.
Source: ir.editasmedicine.com pictogram ir.editasmedicine.com
Pictogram next
08.11.2021
Editas Medicine's GAAP loss in Q3 2021 was $39.082 million, compared to a profit of $7.819 million in the previous year. Revenue decreased 10.5 times to $6.197 million from $62.841 million a year earlier.
Source: ir.editasmedicine.com pictogram ir.editasmedicine.com
Pictogram next
All Editas Medicine news
General information
Company nameEditas Medicine
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Mailing address11 HURLEY ST. CAMBRIDGE MA 02141
Websitewww.editasmedicine.com
Information disclosurewww.sec.gov